" /> " />

Novartis Earnings Estimate

NVS Stock  USD 96.73  0.85  0.89%   
The next projected EPS of Novartis is estimated to be 1.81 with future projections ranging from a low of 1.68 to a high of 1.89. Novartis' most recent 12-month trailing earnings per share (EPS TTM) is at 4.1. Please be aware that the consensus of earnings estimates for Novartis AG ADR is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Novartis is projected to generate 1.81 in earnings per share on the 30th of June 2024. Novartis earnings estimates module stress-tests analyst consensus about projected Novartis AG ADR EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Novartis, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Novartis' earnings estimates, investors can diagnose different trends across Novartis' analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Novartis' Pretax Profit Margin is comparatively stable compared to the past year. Gross Profit Margin is likely to gain to 0.78 in 2024, whereas Gross Profit is likely to drop slightly above 32.3 B in 2024.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

Novartis Earnings Estimation Breakdown

The calculation of Novartis' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Novartis is estimated to be 1.81 with the future projection ranging from a low of 1.68 to a high of 1.89. Please be aware that this consensus of annual earnings estimates for Novartis AG ADR is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.0
1.68
Lowest
Expected EPS
1.81
1.89
Highest

Novartis Earnings Projection Consensus

Suppose the current estimates of Novartis' value are higher than the current market price of the Novartis stock. In this case, investors may conclude that Novartis is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Novartis' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 30th of June 2024Current EPS (TTM)
387.98%
0.0
1.81
4.1

Novartis Earnings History

Earnings estimate consensus by Novartis AG ADR analysts from Wall Street is used by the market to judge Novartis' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Novartis' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Novartis Quarterly Gross Profit

8.75 Billion

Retained Earnings is likely to gain to about 57.8 B in 2024, whereas Price Earnings Ratio is likely to drop 13.62 in 2024. Net Income Applicable To Common Shares is likely to gain to about 9.8 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 1.9 B in 2024.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Novartis' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
95.6696.7397.80
Details
Intrinsic
Valuation
LowRealHigh
87.06105.53106.60
Details
Naive
Forecast
LowNextHigh
93.5194.5895.65
Details
12 Analysts
Consensus
LowTargetHigh
102.60112.75125.15
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Novartis. Your research has to be compared to or analyzed against Novartis' peers to derive any actionable benefits. When done correctly, Novartis' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Novartis AG ADR. Note that many institutional investors and large investment bankers can move markets due to the volume of Novartis assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Novartis. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Novartis' stock price in the short term.

Novartis Earnings per Share Projection vs Actual

Actual Earning per Share of Novartis refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Novartis AG ADR predict the company's earnings will be in the future. The higher the earnings per share of Novartis, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Novartis Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Novartis, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Novartis should always be considered in relation to other companies to make a more educated investment decision.

Novartis Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Novartis' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
null
nullnullnullnull
2024-01-31
2023-12-311.691.53-0.16
2023-10-24
2023-09-301.71.830.13
2023-07-19
2023-06-301.681.830.15
2023-04-25
2023-03-311.551.710.1610 
2023-02-01
2022-12-311.441.520.08
2022-10-25
2022-09-301.551.580.03
2022-07-19
2022-06-301.51.560.06
2022-04-26
2022-03-311.441.460.02
2022-02-02
2021-12-311.411.4-0.01
2021-10-26
2021-09-301.651.710.06
2021-07-21
2021-06-301.531.660.13
2021-04-27
2021-03-311.591.52-0.07
2021-01-26
2020-12-311.361.34-0.02
2020-10-27
2020-09-301.451.520.07
2020-07-21
2020-06-301.311.360.05
2020-04-28
2020-03-311.371.560.1913 
2020-01-29
2019-12-311.291.320.03
2019-10-22
2019-09-301.361.410.05
2019-07-18
2019-06-301.221.340.12
2019-04-24
2019-03-311.161.210.05
2019-01-30
2018-12-311.281.25-0.03
2018-10-18
2018-09-301.31.320.02
2018-07-18
2018-06-301.271.290.02
2018-04-19
2018-03-311.281.280.0
2018-01-24
2017-12-311.191.210.02
2017-10-24
2017-09-301.251.290.04
2017-07-18
2017-06-301.191.210.02
2017-04-25
2017-03-311.111.130.02
2017-01-25
2016-12-311.111.110.0
2016-10-25
2016-09-301.191.230.04
2016-07-19
2016-06-301.181.230.05
2016-04-21
2016-03-311.181.16-0.02
2016-01-27
2015-12-311.181.09-0.09
2015-10-27
2015-09-301.311.27-0.04
2015-07-21
2015-06-301.241.250.01
2015-04-23
2015-03-311.11.290.1917 
2015-01-27
2014-12-311.211.210.0
2014-10-28
2014-09-301.291.370.08
2014-07-17
2014-06-301.41.34-0.06
2014-04-24
2014-03-311.331.28-0.05
2014-01-29
2013-12-311.261.19-0.07
2013-10-22
2013-09-301.311.25-0.06
2013-07-17
2013-06-301.291.30.01
2013-04-24
2013-03-311.281.320.04
2013-01-23
2012-12-311.191.270.08
2012-10-25
2012-09-301.361.34-0.02
2012-07-19
2012-06-301.291.380.09
2012-04-24
2012-03-311.321.27-0.05
2012-01-25
2011-12-311.21.230.03
2011-10-25
2011-09-301.511.45-0.06
2011-07-19
2011-06-301.41.480.08
2011-04-19
2011-03-311.311.410.1
2011-01-27
2010-12-311.251.14-0.11
2010-10-21
2010-09-301.21.270.07
2010-07-15
2010-06-301.131.20.07
2010-04-20
2010-03-311.231.440.2117 
2010-01-26
2009-12-311.11.01-0.09
2009-10-22
2009-09-300.950.92-0.03
2009-07-16
2009-06-300.850.890.04
2009-04-23
2009-03-310.870.870.0
2009-01-28
2008-12-310.790.66-0.1316 
2008-10-20
2008-09-300.950.92-0.03
2008-07-17
2008-06-300.930.980.05
2008-04-21
2008-03-310.891.020.1314 
2008-01-17
2007-12-310.730.4-0.3345 
2007-10-18
2007-09-300.760.68-0.0810 
2007-07-17
2007-06-300.780.830.05
2007-04-23
2007-03-310.840.920.08
2007-01-18
2006-12-310.780.7-0.0810 
2006-10-19
2006-09-300.760.790.03
2006-07-17
2006-06-300.790.73-0.06
2006-04-24
2006-03-310.710.830.1216 
2006-01-19
2005-12-310.710.58-0.1318 
2005-10-18
2005-09-300.720.71-0.01
2005-07-14
2005-06-300.660.70.04
2005-01-20
2004-12-310.60.56-0.04
2004-10-21
2004-09-300.580.630.05
2004-07-20
2004-06-300.590.630.04
2004-04-22
2004-03-310.530.52-0.01
2004-01-22
2003-12-310.530.550.02
2003-10-20
2003-09-300.520.520.0
2003-07-21
2003-06-300.510.520.01
2003-04-15
2003-03-310.460.43-0.03
2003-01-23
2002-12-310.420.450.03
2002-10-17
2002-09-300.440.47130.0313
1998-03-17
1997-12-310.560.51-0.05
1997-09-02
1997-06-300.790.790.0
1997-04-22
1997-03-310.450.520.0715 

About Novartis Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Novartis earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Novartis estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Novartis fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2024
Retained Earnings49.6 B57.8 B
Price Earnings Ratio 14.12  13.62 
Price Earnings To Growth Ratio 0.11  0.11 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
4.987
Dividend Share
3.919
Earnings Share
4.1
Revenue Per Share
22.467
Quarterly Revenue Growth
0.074
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.